Grail stock jumps 33% ahead of FDA multi-cancer blood test review
Grail shares rose 33% ahead of an FDA advisory panel meeting this week to evaluate premarket approval for its blood test designed to detect multiple cancer types early.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.